| Written | 2012-05 | Frank Antonicelli, Philippe Bernard |
| Universite de Reims Champagne-Ardenne, Laboratoire de Dermatologie, CNRS FRE-3481, UFR medecine, Reims, France (FA); CHU de Reims, Hopital Robert Debre, Service de Dermatologie, Reims, France (PB) |
| Identity |
| Alias_names | INP10 |
| SCYB10 | |
| small inducible cytokine subfamily B (Cys-X-Cys), member 10 | |
| chemokine (C-X-C motif) ligand 10 | |
| Alias_symbol (synonym) | IFI10 |
| IP-10 | |
| crg-2 | |
| mob-1 | |
| C7 | |
| gIP-10 | |
| Other alias | |
| HGNC (Hugo) | CXCL10 |
| LocusID (NCBI) | 3627 |
| Atlas_Id | 40218 |
| Location | 4q21.1 [Link to chromosome band 4q21] |
| Location_base_pair | Starts at 76021116 and ends at 76023536 bp from pter ( according to hg19-Feb_2009) [Mapping CXCL10.png] |
| Fusion genes (updated 2017) | Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands) |
| Note | CXCL10 belongs to the CXC subfamily chemokine containing a single and variable amino acid between the two first of four highly conserved cysteine residues. The CXC chemokines can be divided into two subgroups according to the presence of the ELR motif or Glu-Leu-Arg. The ELR+ CXC chemokines are potent promoter of angiogenesis, whereas the ELR- chemokine, such as CXCL10, display angiostatic properties (Belperio et al., 2000). CXCL10 exerts its function through binding to CXCR3, a seven trans-membrane receptor coupled to G proteins. However, three CXCR3 receptor splice variants have been reported, with different properties, resulting in different and divergent CXCL10 biological effects. However, NH2-terminal processing of CXCL10 by proteases results in lower affinity with its CXCR3 receptor, whereas truncated proangiogenic chemokine such as CXCL1 and CXCL8 display enhanced activities (Van Damme et al., 2004). CXCL10 is also named 10kDa interferon γ-induced protein (IP-10), as its secretion by CD4+, CD8+, NK and NK-T cells is dependent on IFN-γ, which is itself mediated by the IL-12 cytokine family. Similarly to IL12p70, the antitumoral effects of IL-27, a new member of the IL-12 family, are mediated either by the IFN-γ/CXCL10 axis, or directly by mimicking the function of IFN-γ (Engel and Neurath, 2010). |
| DNA/RNA |
| Note | CXCL10 gene, localized on the chromosome 4 at band q21, was originally described in 1985 by Luster (Luster et al., 1985). The CXCL10 cDNA arises from 4 exons encoding for a 12 kDa protein (Liu et al., 2011; Luster and Ravetch, 1987), which is widely expressed. Transcription CXCL10, also named IP-10 for Interferon-g-inducible protein 10, is induced by a large range of innate and adaptive immune stimuli that induce the production of IFN type-1 and tye-2. Inflammatory stimuli, such as TNFα, have also been shown to induce CXCL10 expression (Nestle et al., 2009; Nakae et al., 2003). The CXCL10 promoter includes response element for Interferon Regulatory Factor (IRF)1 and for many other transcription factor such as NF-κB, STAT-1, AP-1, FoxA2a, FoxF2, FHXA/FHXB-1, FHXA/FHXB-2 and CEBP (Lu et al., 2011; Clarke et al;, 2010). It was shown recently that CXCL10 promoter also contains a Gamma Activating Sequence (GAS) response element that is activated following homodimerisation of phosphorylated STAT1 (Saha et al., 2010). CXCL10 mRNA is stabilized by S100b protein binding at the 3'-UTR regions (Shanmugam et al., 2006). Multiple alignment sequences of pig, human, mouse, goat and sheep of CXCL10 gene product shows 86, 74, 72, 82 and 83% of homology respectively (Yang et al., 2007). |
| Protein |
 | |
| Description | The primary translation product corresponds to a protein of 12 kDa that is then limited proteolysed in a protein of 98 amino acids mature protein of 10k Da after release of the signal peptide. The three-dimensional crystal structure of CXCL10 has been determined under different conditions, and the protein structural data have the following accession codes 1lv9, 1o7y, and 1o80 in the Protein Data Bank (Fig. 1). CXCL10 activity is bound to its structure and cleavage by MMPs and x-prolyl dipeptidyl peptidase enzymes. The C-terminal truncation leaves CXCL10 under an active form, whereas reduction of its N-terminal tail generates a dominant negative antagonist. Then determination of the balance between the agonists and the antagonist forms is of interest in monitoring the role of CXCL10 in cancer and inflammatory diseases (Casrouge et al., 2012). |
| Expression | CXCL10 is secreted by several cell types including T lymphocytes, neutrophils, monocytes, splenocytes, endothelial cells, fibroblasts, keratinocytes, osteoblasts, astrocytes and smooth muscle cells. |
| Localisation | CXCL10 is a secreted protein present in body fluids and in tissues. |
| Function | CXCL10 is a pleiotropic molecule that exerts several functions according to the cell type and the CXCL10 receptor isoform they express. The mature form of CXCL10 and two other members of the CXC chemokine family, CXCL9 (Mig) and CXCL11 (I-TAC), bind the CXCR3 receptor, with a higher affinity for the CXCR3A than the CXCR3B isoform. A third isoform of CXCR3 (CXCR3-alt) is always co-expressed at a very low level with CXCR3A, but its function has still not been determined ( Lo et al., 2010; Aksoy et al., 2006). According to cell types and CXCL10 receptors, several signalling pathways can be activated. Following to CXCL10 binding, CXCR3A activates Erk1/2, JNK and PI3K/AKT pathways (Liu et al., 2011; Ji et al., 2008; Maru et al., 2008; Aksoy et al., 2006; Loetscher et al., 1998), while CXCR3B stimulated the adenylyl cyclase cascade and p38/MAPK (Aksoy et al., 2006; Giuliani et al., 2006; Lazzeri and Romagnani, 2005; Romagnani et al., 2005; Kim et al., 2002). |
| Homology | CXCL10 has significant amino-acid homology to platelet factor-4 and beta-thromboglobulin, two chemotatic proteins released by platelet (Luster et al., 1985). |
| Implicated in |
| Note | |
| Entity | Brain cancer |
| Note | Using mice models, it has been shown an elevated CXCL10 level upon nonsteroidal anti-inflammatory drugs is associated with enhanced cytotoxic T lymphocytes infiltration and reduced gliomagenesis (Fujita et al., 2011). Accordingly, Glioma-bearing CXCR3-deficient mice had significantly shorter median survival time and reduced numbers of tumor-infiltrated natural killer and natural killer T cells with respect to wild type mice (Liu et al., 2011). In this line, a therapy combining CXCL10 overexpression with glioma lysate-pulsed DCs revealed synergistic effect against glioma progression (Jiang et al., 2009). |
| Entity | Breast cancer |
| Note | In vitro study demonstrated that in breast cancer cells Ras-induced overexpression of CXCL10 is mediated primarily through the Raf and phosphatidylinositol 3-kinase signaling pathways. The expression of the splice variant CXCR3-B, known to inhibit cell proliferation, is significantly down-regulated by Ras, suggesting that CXCL10-mediated breast cancer cell proliferation likely involves CXCR3-A (Datta et al., 2006). Besides, in murine breast cancer CXCL10 impairs tumor growth and metastasis formation through recruitment of natural killer (NK) cells and tumor-suppressive T lymphocytes. In such models, CXCL10 expression is controlled by PGE2 and cyclooxygenase inhibition (Bronger et al., 2012). The anti-tumoral immune response is favored by IFN-γ secreted from NK cells which promotes the production of CXCL10 from breast cancer cells, and in turn accelerates the migration of CXCR3-expressing NK cells into the tumor site. Then, activation of autologous NK cells could represent a potential therapeutic adoptive transfer (Kajitani et al., 2012). |
| Entity | Colorectal cancer |
| Note | Colorectal cancer is a complex disease involving immune defense mechanisms. Data from 108 patients showed that in patients with prolonged disease-free survival, CXCL10 correlated with different subsets of immune cells displaying particular TCR repertoire and with high densities of T-cell subpopulations within specific tumor regions (Mlecnik et al., 2010). Conversely, CXCL10 level increased with advanced colorectal cancer, with vascular invasion and distant metastasis. Then, CXCL10 was associated with poor prognosis and liver metastasis (Toiyama et al., 2012). CXCL10 deleterious effects are triggered by TNFα-induced NF-kB transcriptional activation and can be suppressed by 3'-Chloro-5,7-dimethoxyisoflavone, a synthetic isoflavone derivative (Shin et al., 2011). |
| Entity | Liver cancer |
| Note | Among a 14-gene immune signature, CXCL10 contributes at predicting patient survival with hepatocellular carcinoma issued from two series includes, irrespectively of patient ethnicity and disease aetiology. In this study, CXCL10 correlates with markers of T helper 1 (Th1), CD8(+) T and natural killer (NK) cells, and good prognosis for patients with early disease (stages I and II), but not in late disease stages III and IV (Chew et al., 2012). Besides, use of an orthotopic liver tumor nude mice model with distant metastatic potential, adiponectin downregulates the ROCK/IP10/MMP-9 signaling pathway from tumor cell, and inhibits liver tumor growth and metastasis by reducing the formation of lamellipodia, which contribute to cell migration (Man et al., 2010). Of interest, CXCL10 level in different hepatocellular carcinoma cell lines is determined by melatonin concentration, which therefore could present relevant application for patients with hepatocellular carcinoma (Lin and Chuang, 2010). Loss of hepatocyte c-Met receptor causes a strong deregulation of chemotactic and inflammatory signaling such as CXCL10, and alters hepatic microenvironment and aggravated hepatic fibrogenesis (Marquardt et al., 2012). |
| Entity | Lung cancer |
| Note | CXCR3 expression in CD4(+) T cells from pleural plaque and mesothelioma is significantly reduced compared with that from healthy donors, and CD4(+)CXCR3(+) T cells from mesothelioma showed an inverse correlation with its ligand CXCL10/IP10 in plasma. This suggests that CXCR3and CXCL10/IP10 may be candidates to detect and monitor the antitumor immune function in patients with lung cancer and mesothelioma (Maeda et al., 2011). In this respect, although a synergistic antitumor effect is not observed in a combined treatment using CXCL10 and CXCL11, a chimeric molecule engineered by substituting the N-terminal and N-loop region of CXCL10 with those of CXCL11 promotes regression of established tumors and remarkably prolonges survival of mice compared to these chemokines used either alone or in combination (Wang et al., 2010). In this line, a chimeric γc homeostatic cytokine, IL-7/IL-7Rα-Fc promotes afferent and efferent antitumor responses in lung cancer by increasing CXCL10 expression, tumor macrophage infiltrates, frequencies of T and NK cells, effector memory T cells and T cell cytolytic activity against parental tumor cells (Andersson et al., 2011). |
| Entity | Lymphoma |
| Note | CXCL10 was discovered following treatment of a lymphoma cell line (U937) with IFN-γ (Luster et al., 1985). Recently, a prognostic value was attributed to this chemokine in large-cell lymphoma and myelodysplastic syndromes suggesting a deleterious pathogenic contribution of this chemokine in these diseases development (Pardanani et al., 2011). Likewise, CXCL10 has been associated with epidermotropism of cutaneous T-lymphoma cells, which could partly explain the clonal expansion of lymphocytes in the skin in the absence of systemic involvement (Sugaya, 2011). |
| Entity | Melanoma |
| Note | The antitumoral effects of CXCL10 were demonstrated in vivo using different animal models (Antonicelli et al., 2011; Feldman et al., 2002). Notably, it was shown that suppression of melanoma growth by thalidomide was associated with up-regulation of CXCL10 in the spleen of mice (Kawamata et al., 2006). In Human, induction of IP-10/CXCL10 secretion was proposed as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma (Mohty et al., 2010). High level expression of CXCL10 was detected in situ in regressive human primary melanoma concomitantly with the CXCR3+ lymphocyte recruitment (Wenzel et al., 2005). A high CXCL10 concentration is also secreted by PBMC from patients with melanoma in regression compared to patients with melanoma in progression (Antonicelli et al., 2011). Besides its chemotactic activity, this chemokine interacts either directly with melanoma cells to control tumour progression (Antonicelli et al., 2011) or reduces the microvessel density (Yang and Richmond, 2004). |
| Entity | Ovarian cancer |
| Note | Analysis of 201 ovarian cancer patients revealed that tumor-infiltrating Th17 cells are positively associated with effector cells, and are negatively associated with tumor-infiltrating regulatory T cells. The synergistic action between IL-17 and interferon-gamma, stimulate CXCL9 and CXCL10 production to recruit effector T cells and therefore contribute to protective human tumor immunity (Kryczek et al., 2009). Viral infection increases detection and elimination by immune cells. Viral infection stimulates RNA helicase retinoic acid-inducible gene-I induced CXCL10 from ovarian cancer cells and HLA class I upregulation. These cells become succeptible to apoptosis, phagocytose by monocytes and monocyte-derived dendritic cells, which in turn upregulated HLA class I/II and costimulatory molecules and released CXCL10 and IFN-alpha (Kübler et al., 2010). |
| Entity | Prostate cancer |
| Note | In prostate cancer, CXCL10/IP10 promotes cell motility and invasiveness via PLCβ3 and µ-calpain activation. Meanwhile, CXCR3A mRNA level is upregulated while CXCR3B mRNA is downregulated in these prostate cancer specimens (Wu et al., 2012). However, in invitro study showed that CXCL10 inhibits prostate cancer cell proliferation and decreased PSA production by up-regulation of CXCR3 receptor suggesting that CXCL10 may be potentially useful in the treatment of prostate cancer (Nagpal et al., 2006). In this line, neoadjuvant hormone therapy boosts the expression CXCL10 in the glandular epithelium of normal prostate tissue, and restored the CD8(+) lymphocyte depletion occurring in prostate cancer, whereas it significantly increased the CD4(+) lymphocyte infiltrate. However, it also increased the number of T regulatory cells, and then might have no impact on disease free survival (Sorrentino et al., 2011). |
| Entity | Immunity |
| Note | Peripheral inflammatory markers are often used as predictor of tumour development. Determination of high level of CXCL10 in peripheral liquids is therefore a marker of host immune response, especially Th1 orientated T-cells, which have been shown to be associated with a better prognosis for many cancer types including brain (Elstner et al., 2011; Okada, 2009), hepatic (Moura et al., 2009) and colorectal (Engel and Neurath, 2010) neoplasms, or melanoma (Antonicelli et al., 2011; Mohty et al., 2010). In this line, natural Killer lymphocytes endowed immunoregulatory functions by secreting IFN-γ. Therefore these cells have been successfully employed to treat patients with myeloid leukaemia and other haematological malignancies (Maghazachi, 2010). Animal model showed apparent overexpression in tissue with tumour undergoing regression reflecting an immune host response (Tosato et al., 1998). Similarly, expression of CXCL10 as determined by immunocytochemistry was increased in tumour skin frozen sections (Daliani et al., 1998). Increased CXCL10 expression at site of injury could enhance the homing of immune cells expression the CXCR3 receptor (Okada, 2009). Recruited Th1 lymphocytes may be responsible for enhanced IFN-γ and TNF-α production, which in turn stimulates CXCL10 secretion from a variety of cells, therefore creating an amplification feedback loop (Antonelli et al., 2008). This chemotactic-based amplification loop is impaired when the NH-2 terminal CXCL10 extremity is truncated (Persano et al., 2011; Proost et al., 2001). Although such sustained inflammatory and immune response is of interest to reduce tumour progression, it also may predispose or lead to autoimmune disorders (Lacotte et al., 2009; Antonelli et al., 2008; Liu et al., 2008; Luster et al., 1985). |
| Entity | Angiostasis |
| Note | As an ELR- CXC chemokine, CXCL10 displays angiostatic effects through binding to its CXCR3B receptor subunit. This anti-angiogenic effect is processed through inhibition of proliferation and induction of apoptosis of endothelial cells (Liu et al., 2011; Feldman et al., 2006). These effects are mediated by a downstream CXCR3B activation of the p38 pathway (Petrai et al., 2008). CXCL10 also antagonizes the pro-angiogenic effects of bFGF and VEGF (Aronica et al., 2009; Sato et al., 2007). Of note, the NH-2 CXCL10 truncation impaired its signalling cascade effects with modifying its anti-angiogenic properties (Struyf et al., 2011; Proost et al., 2001). Consequently, CXCL10 level has been inversely correlated with tumour progression such as in lymphoma, squamous cells carcinoma, carcinoma, melanoma and many others tumour types. However, preclinical studies have clearly indicated that such cytostatic factor need long-term administration to display an antitumoral effect, which furthermore is only really efficient during the early phase of tumour progression (Persano et al., 2007). |
| Bibliography |
| CXCR3 surface expression in human airway epithelial cells: cell cycle dependence and effect on cell proliferation. |
| Aksoy MO, Yang Y, Ji R, Reddy PJ, Shahabuddin S, Litvin J, Rogers TJ, Kelsen SG. |
| Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L909-18. Epub 2005 Dec 9. |
| PMID 16339779 |
| Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer. |
| Andersson A, Srivastava MK, Harris-White M, Huang M, Zhu L, Elashoff D, Strieter RM, Dubinett SM, Sharma S. |
| Clin Cancer Res. 2011 Jun 1;17(11):3660-72. |
| PMID 21636553 |
| Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. |
| Antonelli A, Ferri C, Ferrari SM, Colaci M, Fallahi P. |
| Autoimmun Rev. 2008 Oct;8(1):18-23. Epub 2008 Aug 15. (REVIEW) |
| PMID 18708169 |
| CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo. |
| Antonicelli F, Lorin J, Kurdykowski S, Gangloff SC, Le Naour R, Sallenave JM, Hornebeck W, Grange F, Bernard P. |
| Br J Dermatol. 2011 Apr;164(4):720-8. doi: 10.1111/j.1365-2133.2010.10176.x. Epub 2011 Mar 16. |
| PMID 21155750 |
| Antitumor/antiestrogenic effect of the chemokine interferon inducible protein 10 (IP-10) involves suppression of VEGF expression in mammary tissue. |
| Aronica SM, Raiber L, Hanzly M, Kisela C. |
| J Interferon Cytokine Res. 2009 Feb;29(2):83-92. |
| PMID 19014340 |
| CXC chemokines in angiogenesis. |
| Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM. |
| J Leukoc Biol. 2000 Jul;68(1):1-8. (REVIEW) |
| PMID 10914483 |
| Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. |
| Bronger H, Kraeft S, Schwarz-Boeger U, Cerny C, Stockel A, Avril S, Kiechle M, Schmitt M. |
| Breast Cancer Res. 2012 Feb 14;14(1):R30. [Epub ahead of print] |
| PMID 22333315 |
| Discrimination of agonist and antagonist forms of CXCL10 in biological samples. |
| Casrouge A, Bisiaux A, Stephen L, Schmolz M, Mapes J, Pfister C, Pol S, Mallet V, Albert ML. |
| Clin Exp Immunol. 2012 Jan;167(1):137-48. doi: 10.1111/j.1365-2249.2011.04488.x. |
| PMID 22132893 |
| Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. |
| Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP. |
| Gut. 2012 Mar;61(3):427-38. Epub 2011 Sep 19. |
| PMID 21930732 |
| TNFgamma and IFNgamma synergistically enhance transcriptional activation of CXCL10 in human airway smooth muscle cells via STAT-1, NF-?B, and the transcriptional coactivator CREB-binding protein. |
| Clarke DL, Clifford RL, Jindarat S, Proud D, Pang L, Belvisi M, Knox AJ. |
| J Biol Chem. 2010 Sep 17;285(38):29101-10. |
| PMID 20833730 |
| Tumor necrosis factor-alpha and interferon-gamma, but not HTLV-I tax, are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferon-inducible protein-10. |
| Daliani D, Ulmer RA, Jackow C, Pugh W, Gansbacher B, Cabanillas F, Duvic M, Sarris AH. |
| Leuk Lymphoma. 1998 Apr;29(3-4):315-28. (REVIEW) |
| PMID 9684929 |
| Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. |
| Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S. |
| Cancer Res. 2006 Oct 1;66(19):9509-18. |
| PMID 17018607 |
| Identification of diagnostic serum protein profiles of glioblastoma patients. |
| Elstner A, Stockhammer F, Nguyen-Dobinsky TN, Nguyen QL, Pilgermann I, Gill A, Guhr A, Zhang T, von Eckardstein K, Picht T, Veelken J, Martuza RL, von Deimling A, Kurtz A. |
| J Neurooncol. 2011 Mar;102(1):71-80. Epub 2010 Jul 9. |
| PMID 20617365 |
| Anticancer properties of the IL-12 family--focus on colorectal cancer. |
| Engel MA, Neurath MF. |
| Curr Med Chem. 2010;17(29):3303-8. (REVIEW) |
| PMID 20712574 |
| Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. |
| Feldman AL, Friedl J, Lans TE, Libutti SK, Lorang D, Miller MS, Turner EM, Hewitt SM, Alexander HR. |
| Int J Cancer. 2002 May 1;99(1):149-53. |
| PMID 11948506 |
| Interferon gamma-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. |
| Feldman ED, Weinreich DM, Carroll NM, Burness ML, Feldman AL, Turner E, Xu H, Alexander HR Jr. |
| Ann Surg Oncol. 2006 Jan;13(1):125-33. Epub 2006 Jan 1. |
| PMID 16378159 |
| COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. |
| Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, Ohlfest JR, Okada H. |
| Cancer Res. 2011 Apr 1;71(7):2664-74. Epub 2011 Feb 15. |
| PMID 21324923 |
| CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. |
| Giuliani N, Bonomini S, Romagnani P, Lazzaretti M, Morandi F, Colla S, Tagliaferri S, Lasagni L, Annunziato F, Crugnola M, Rizzoli V. |
| Haematologica. 2006 Nov;91(11):1489-97. |
| PMID 17082008 |
| Human type II pneumocyte chemotactic responses to CXCR3 activation are mediated by splice variant A. |
| Ji R, Lee CM, Gonzales LW, Yang Y, Aksoy MO, Wang P, Brailoiu E, Dun N, Hurford MT, Kelsen SG. |
| Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1187-96. Epub 2008 Mar 28. |
| PMID 18375741 |
| Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma. |
| Jiang XB, Lu XL, Hu P, Liu RE. |
| Vaccine. 2009 Oct 19;27(44):6210-6. Epub 2009 Aug 20. |
| PMID 19699331 |
| Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells. |
| Kajitani K, Tanaka Y, Arihiro K, Kataoka T, Ohdan H. |
| Breast Cancer Res Treat. 2012 Jul;134(1):139-55. Epub 2012 Jan 20. |
| PMID 22261932 |
| Thalidomide suppresses melanoma growth by activating natural killer cells in mice. |
| Kawamata A, Ito D, Odani T, Isobe T, Iwase M, Hatori M, Nagumo M. |
| Oncol Rep. 2006 Dec;16(6):1231-6. |
| PMID 17089043 |
| Inhibition of endothelial cell survival and angiogenesis by protein kinase A. |
| Kim S, Bakre M, Yin H, Varner JA. |
| J Clin Invest. 2002 Oct;110(7):933-41. |
| PMID 12370271 |
| Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. |
| Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W. |
| Blood. 2009 Aug 6;114(6):1141-9. Epub 2009 May 21. |
| PMID 19470694 |
| Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. |
| Kubler K, Gehrke N, Riemann S, Bohnert V, Zillinger T, Hartmann E, Polcher M, Rudlowski C, Kuhn W, Hartmann G, Barchet W. |
| Cancer Res. 2010 Jul 1;70(13):5293-304. Epub 2010 Jun 15. |
| PMID 20551064 |
| CXCR3, inflammation, and autoimmune diseases. |
| Lacotte S, Brun S, Muller S, Dumortier H. |
| Ann N Y Acad Sci. 2009 Sep;1173:310-7. (REVIEW) |
| PMID 19758167 |
| CXCR3-binding chemokines: novel multifunctional therapeutic targets. |
| Lazzeri E, Romagnani P. |
| Curr Drug Targets Immune Endocr Metabol Disord. 2005 Mar;5(1):109-18. (REVIEW) |
| PMID 15777209 |
| Pharmacologic concentrations of melatonin have diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. |
| Lin ZY, Chuang WL. |
| Biomed Pharmacother. 2010 Dec;64(10):659-62. Epub 2010 Sep 25. |
| PMID 20970952 |
| Chemokine receptor CXCR3 promotes growth of glioma. |
| Liu C, Luo D, Reynolds BA, Meher G, Katritzky AR, Lu B, Gerard CJ, Bhadha CP, Harrison JK. |
| Carcinogenesis. 2011 Feb;32(2):129-37. Epub 2010 Nov 3. |
| PMID 21051441 |
| Chemokines and autoimmune thyroid diseases. |
| Liu C, Papewalis C, Domberg J, Scherbaum WA, Schott M. |
| Horm Metab Res. 2008 Jun;40(6):361-8. Epub 2008 Apr 16. (REVIEW) |
| PMID 18418812 |
| CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. |
| Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, Stiles JK. |
| Cytokine Growth Factor Rev. 2011 Jun;22(3):121-30. Epub 2011 Jul 29. |
| PMID 21802343 |
| CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. |
| Lo BK, Yu M, Zloty D, Cowan B, Shapiro J, McElwee KJ. |
| Am J Pathol. 2010 May;176(5):2435-46. Epub 2010 Mar 12. |
| PMID 20228225 |
| Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. |
| Loetscher M, Loetscher P, Brass N, Meese E, Moser B. |
| Eur J Immunol. 1998 Nov;28(11):3696-705. |
| PMID 9842912 |
| Regulation of influenza A virus induced CXCL-10 gene expression requires PI3K/Akt pathway and IRF3 transcription factor. |
| Lu X, Masic A, Liu Q, Zhou Y. |
| Mol Immunol. 2011 Jul;48(12-13):1417-23. Epub 2011 Apr 16. |
| PMID 21497908 |
| Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). |
| Luster AD, Ravetch JV. |
| J Exp Med. 1987 Oct 1;166(4):1084-97. |
| PMID 2443596 |
| Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. |
| Luster AD, Unkeless JC, Ravetch JV. |
| Nature. 1985 Jun 20-26;315(6021):672-6. |
| PMID 3925348 |
| Decreased CXCR3 expression in CD4+ T cells exposed to asbestos or derived from asbestos-exposed patients. |
| Maeda M, Nishimura Y, Hayashi H, Kumagai N, Chen Y, Murakami S, Miura Y, Hiratsuka J, Kishimoto T, Otsuki T. |
| Am J Respir Cell Mol Biol. 2011 Oct;45(4):795-803. Epub 2011 Feb 25. |
| PMID 21357438 |
| Role of chemokines in the biology of natural killer cells. |
| Maghazachi AA. |
| Curr Top Microbiol Immunol. 2010;341:37-58. (REVIEW) |
| PMID 20369317 |
| Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. |
| Man K, Ng KT, Xu A, Cheng Q, Lo CM, Xiao JW, Sun BS, Lim ZX, Cheung JS, Wu EX, Sun CK, Poon RT, Fan ST. |
| Clin Cancer Res. 2010 Feb 1;16(3):967-77. Epub 2010 Jan 26. |
| PMID 20103676 |
| Loss of c-Met accelerates development of liver fibrosis in response to CCl(4) exposure through deregulation of multiple molecular pathways. |
| Marquardt JU, Seo D, Gomez-Quiroz LE, Uchida K, Gillen MC, Kitade M, Kaposi-Novak P, Conner EA, Factor VM, Thorgeirsson SS. |
| Biochim Biophys Acta. 2012 Jun;1822(6):942-51. Epub 2012 Feb 22. |
| PMID 22386877 |
| Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation. |
| Maru SV, Holloway KA, Flynn G, Lancashire CL, Loughlin AJ, Male DK, Romero IA. |
| J Neuroimmunol. 2008 Aug 13;199(1-2):35-45. Epub 2008 Jun 9. |
| PMID 18538864 |
| Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. |
| Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, Pages F, Trajanoski Z, Galon J. |
| Gastroenterology. 2010 Apr;138(4):1429-40. Epub 2009 Nov 10. |
| PMID 19909745 |
| Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma. |
| Mohty AM, Grob JJ, Mohty M, Richard MA, Olive D, Gaugler B. |
| Immunobiology. 2010;215(2):113-23. Epub 2009 May 17. |
| PMID 19450896 |
| Soluble inflammatory markers as predictors of hepatocellular damage and therapeutic response in chronic hepatitis C. |
| Moura AS, Carmo RA, Teixeira AL, Rocha MO. |
| Braz J Infect Dis. 2009 Oct;13(5):375-82. (REVIEW) |
| PMID 20428640 |
| Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation. |
| Nagpal ML, Davis J, Lin T. |
| Biochim Biophys Acta. 2006 Sep;1762(9):811-8. Epub 2006 Jul 25. |
| PMID 16934957 |
| IL-1-induced tumor necrosis factor-alpha elicits inflammatory cell infiltration in the skin by inducing IFN-gamma-inducible protein 10 in the elicitation phase of the contact hypersensitivity response. |
| Nakae S, Komiyama Y, Narumi S, Sudo K, Horai R, Tagawa Y, Sekikawa K, Matsushima K, Asano M, Iwakura Y. |
| Int Immunol. 2003 Feb;15(2):251-60. |
| PMID 12578855 |
| Psoriasis. |
| Nestle FO, Kaplan DH, Barker J. |
| N Engl J Med. 2009 Jul 30;361(5):496-509. (REVIEW) |
| PMID 19641206 |
| Brain tumor immunotherapy with type-1 polarizing strategies. |
| Okada H. |
| Ann N Y Acad Sci. 2009 Sep;1174:18-23. (REVIEW) |
| PMID 19769732 |
| IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. |
| Pardanani A, Finke C, Lasho TL, Al-Kali A, Begna KH, Hanson CA, Tefferi A. |
| Leukemia. 2012 Apr;26(4):693-9. doi: 10.1038/leu.2011.251. Epub 2011 Sep 13. |
| PMID 21912394 |
| Anti-angiogenic gene therapy of cancer: current status and future prospects. |
| Persano L, Crescenzi M, Indraccolo S. |
| Mol Aspects Med. 2007 Feb;28(1):87-114. Epub 2007 Jan 11. (REVIEW) |
| PMID 17306361 |
| Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. |
| Petrai I, Rombouts K, Lasagni L, Annunziato F, Cosmi L, Romanelli RG, Sagrinati C, Mazzinghi B, Pinzani M, Romagnani S, Romagnani P, Marra F. |
| Int J Biochem Cell Biol. 2008;40(9):1764-74. Epub 2008 Jan 16. |
| PMID 18291705 |
| Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. |
| Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, Detheux M, Parmentier M, Durinx C, Lambeir AM, Neyts J, Liekens S, Maudgal PC, Billiau A, Van Damme J. |
| Blood. 2001 Dec 15;98(13):3554-61. |
| PMID 11739156 |
| CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. |
| Romagnani P, Maggi L, Mazzinghi B, Cosmi L, Lasagni L, Liotta F, Lazzeri E, Angeli R, Rotondi M, Fili L, Parronchi P, Serio M, Maggi E, Romagnani S, Annunziato F. |
| J Allergy Clin Immunol. 2005 Dec;116(6):1372-9. |
| PMID 16337473 |
| Gene modulation and immunoregulatory roles of interferon gamma. |
| Saha B, Jyothi Prasanna S, Chandrasekar B, Nandi D. |
| Cytokine. 2010 Apr;50(1):1-14. Epub 2009 Dec 29. (REVIEW) |
| PMID 20036577 |
| Expression of interferon-gamma-inducible protein 10 related to angiogenesis in uterine endometrial cancers. |
| Sato E, Fujimoto J, Tamaya T. |
| Oncology. 2007;73(3-4):246-51. Epub 2008 Apr 17. |
| PMID 18424889 |
| Interferon-gamma-inducible protein (IP)-10 mRNA stabilized by RNA-binding proteins in monocytes treated with S100b. |
| Shanmugam N, Ransohoff RM, Natarajan R. |
| J Biol Chem. 2006 Oct 20;281(42):31212-21. Epub 2006 Aug 24. |
| PMID 16931519 |
| 3'-Chloro-5,7-dimethoxyisoflavone inhibits TNF?-induced CXCL10 gene transcription by suppressing the NF-?B pathway in HCT116 human colon cancer cells. |
| Shin SY, Hyun J, Lim Y, Lee YH. |
| Int Immunopharmacol. 2011 Dec;11(12):2104-11. Epub 2011 Sep 22. |
| PMID 21945666 |
| Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. |
| Sorrentino C, Musiani P, Pompa P, Cipollone G, Di Carlo E. |
| Clin Cancer Res. 2011 Mar 15;17(6):1571-81. Epub 2010 Dec 15. |
| PMID 21159885 |
| Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. |
| Struyf S, Salogni L, Burdick MD, Vandercappellen J, Gouwy M, Noppen S, Proost P, Opdenakker G, Parmentier M, Gerard C, Sozzani S, Strieter RM, Van Damme J. |
| Blood. 2011 Jan 13;117(2):480-8. Epub 2010 Oct 27. |
| PMID 20980681 |
| [Cutaneous lymphoma and chemokine]. |
| Sugaya M. |
| Nihon Rinsho Meneki Gakkai Kaishi. 2011;34(2):91-8. (REVIEW) |
| PMID 21628851 |
| Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer. |
| Toiyama Y, Fujikawa H, Kawamura M, Matsushita K, Saigusa S, Tanaka K, Inoue Y, Uchida K, Mohri Y, Kusunoki M. |
| Int J Oncol. 2012 Feb;40(2):560-6. doi: 10.3892/ijo.2011.1247. Epub 2011 Oct 31. |
| PMID 22038159 |
| Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. |
| Tosato G, Teruya-Feldstein J, Setsuda J, Pike SE, Jones KD, Jaffe ES. |
| Springer Semin Immunopathol. 1998;20(3-4):405-23. (REVIEW) |
| PMID 9870254 |
| Chemokine-protease interactions in cancer. |
| Van Damme J, Struyf S, Opdenakker G. |
| Semin Cancer Biol. 2004 Jun;14(3):201-8. (REVIEW) |
| PMID 15246056 |
| Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy. |
| Wang P, Yang X, Xu W, Li K, Chu Y, Xiong S. |
| Cancer Immunol Immunother. 2010 Nov;59(11):1715-26. Epub 2010 Aug 13. |
| PMID 20706716 |
| Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. |
| Wenzel J, Bekisch B, Uerlich M, Haller O, Bieber T, Tuting T. |
| Am J Clin Pathol. 2005 Jul;124(1):37-48. |
| PMID 15923172 |
| Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. |
| Wu Q, Dhir R, Wells A. |
| Mol Cancer. 2012 Jan 11;11:3. |
| PMID 22236567 |
| Molecular characterization of cDNA encoding porcine IP-10 and induction of porcine endothelial IP-10 in response to human TNF-alpha. |
| Yang J, Choi I, Kim SD, Kim ES, Cho B, Kim JY, Ahn C. |
| Vet Immunol Immunopathol. 2007 May 15;117(1-2):124-8. Epub 2007 Feb 3. |
| PMID 17328963 |
| The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. |
| Yang J, Richmond A. |
| Mol Ther. 2004 Jun;9(6):846-55. |
| PMID 15194051 |
| Citation |
| This paper should be referenced as such : |
| Antonicelli, F ; Bernard, P |
| CXCL10 (chemokine (C-X-C motif) ligand 10) |
| Atlas Genet Cytogenet Oncol Haematol. 2012;16(11):782-788. |
| Free journal version : [ pdf ] [ DOI ] |
| On line version : http://AtlasGeneticsOncology.org/Genes/CXCL10ID40218ch4q21.html |
| External links |
| REVIEW articles | automatic search in PubMed |
| Last year publications | automatic search in PubMed |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Thu Oct 12 16:19:45 CEST 2017 |
For comments and suggestions or contributions, please contact us